In addition to the financial results, TELA Bio announced the promotion of Howard Langstein, MD, FACS to Chief Medical Officer, effective March 1, 2026. The company also secured a credit facility of up to $70 million from Perceptive Advisors, which includes an initial loan of $60 million and an additional $10 million available upon meeting certain conditions.
CEO Antony Koblish expressed confidence in the company’s trajectory, stating, "We closed 2025 with our strongest quarterly revenue on record, delivering $20.9 million and 18% growth over Q4 2024 while holding operating expenses essentially flat for the year, demonstrating the operating leverage we expect to continue to see in the years ahead." He further emphasized the strength of the leadership team and the sales force, which has expanded to 88 quota-carrying representatives, positioning the company for continued growth in 2026.
The company’s gross profit for Q4 2025 was reported at $13.8 million, representing a gross margin of 65.9%, an improvement from 63.6% in Q4 2024. Operating expenses increased to $20.4 million, primarily due to higher compensation costs and increased study and development costs. Despite these expenses, TELA Bio reported a loss from operations of $6.6 million, an improvement from a loss of $8.4 million in the same quarter of the previous year.
Looking ahead, TELA Bio has provided guidance for 2026, projecting at least 8% revenue growth over 2025. The company is optimistic about its ability to achieve profitability without the need for additional capital raises, supported by its strengthened sales force and operational efficiencies.
